The massive capital raise (~$1.075B) following positive Phase 3 data signals aggressive preparation for commercial launch of VAX-31. The dilutive equity component (~7.4M shares at $64.00) and convertible note overhang (~$575M at $89.60 conversion) create near-term pressure on PCVX stock. Monitor upcoming OPUS-2 and OPUS-3 topline data for VAX-31 and the company's cash burn rate.
Price Chart
Executive Summary
Vaxcyte entered into a First Supplemental Indenture to issue $575M aggregate principal amount of 1.50% Convertible Senior Notes due 2032 (including the underwriters' over-allotment option), and concurrently closed a $500M equity offering of 7,412,500 shares of common stock and pre-funded warrants at $64.00/$63.999 per share. The combined ~$959M in gross proceeds (before expenses) will fund clinical development of VAX-31, manufacturing scale-up, and commercial launch preparations. The capital raise follows positive Phase 3 OPUS-1 topline results for VAX-31 and is dilutive to existing common shareholders.
Key Facts
- Issued $575M aggregate principal amount of 1.50% Convertible Senior Notes due 2032 (including $75M over-allotment option exercised)
- Concurrently sold 7,412,500 shares of common stock at $64.00/share and pre-funded warrants for 400,000 shares at $63.999/warrant
- Combined gross proceeds of approximately $1.075B ($500M notes + $500M equity + $75M over-allotment)
- Initial conversion price on notes is ~$89.60 per share, representing ~40% premium to the $64.00 equity offering price
- Proceeds to fund VAX-31 clinical development, manufacturing scale-up, and commercial launch preparations
- Filing follows positive Phase 3 OPUS-1 topline results for VAX-31 announced October 5, 2026
- Company expected to report ~$2.3B in cash, cash equivalents, and investments as of September 30, 2026
Financial Impact
Combined capital raise of ~$1.075B in gross proceeds, with $575M in convertible notes and ~$500M in equity/pre-funded warrants. Dilution of ~7.4M shares (plus up to 1.17M option shares) and potential future dilution from note conversion at $89.60/share.
Risk Factors
- Significant dilution from 7.4M new shares and potential conversion of $575M notes at $89.60/share
- Execution risk in scaling manufacturing and commercial launch for VAX-31
- Convertible note interest expense ($8.6M annually) adds fixed cost
- Stock price below conversion price ($89.60) could limit note conversion and increase redemption risk
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-419174 |
| Document: d150490dex11.htm | 0001193125-26-419174 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $70.65 $63.68 | ▲ +9.87% | ▲ +8.37% | $60.67 (+14.13%) |
Oct 8, 2026 19d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.67 (+15.00%) |
Oct 8, 2026 19d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.67 (+15.00%) |
Oct 5, 2026 22d ago | 424B5 | $66.70 $66.80 | ▲ +0.15% | ▲ +0.29% | $60.67 (−9.04%) |
Oct 5, 2026 22d ago | 424B5 | $66.70 $66.80 | ▼ −0.15% | ▼ −0.29% | $60.67 (+9.04%) |
Oct 5, 2026 22d ago | 8-K | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Oct 5, 2026 22d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Oct 4, 2026 23d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Aug 5, 2026 11w ago | Insider Cluster | $58.89 $58.86 | ▼ −0.05% | ▼ −1.26% | $60.67 (+3.02%) |
Jul 6, 2026 16w ago | Insider Cluster | $60.67 $56.21 | ▼ −7.35% | ▼ −7.90% | $60.67 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers